Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
November 3, 2021 6:00 AM EDT$14.7 million in net revenue for the third quarter 2021 (122% increase from second quarter 2021)
Steady increases in LUPKYNIS Patient Start Forms, Conversion Rates and Payer Coverage
Addition of two preclinical assets with potential in rare autoimmune conditions to grow and diversify the pipeline
Conference call to be hosted today at 8:30 a.m. ET
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter ended September 30, 2021. Amounts, unless... More
